At what estimated glomerular filtration rate should rosuvastatin be stopped?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rosuvastatin Does Not Need to Be Stopped Based on eGFR Alone

Rosuvastatin should not be routinely discontinued at any specific eGFR level, but dose adjustment is required when eGFR falls below 30 mL/min/1.73 m².

Dosing Recommendations by Kidney Function

According to the FDA-approved prescribing information for rosuvastatin, patients with severe renal impairment (eGFR <30 mL/min/1.73 m² and not on hemodialysis) should initiate therapy at 5 mg once daily and should not exceed 10 mg once daily 1. This is a dose limitation, not a contraindication to use.

The KDIGO guidelines explicitly state that statins show no increase in toxicity even in patients with eGFR <30 mL/min/1.73 m² or on dialysis 2. Clinical trials of statins in patients with eGFR <15 mL/min/1.73 m² or on dialysis demonstrated no excess toxicity 2.

Key Clinical Considerations

When to Adjust (Not Stop):

  • eGFR <30 mL/min/1.73 m²: Reduce to maximum 10 mg daily 1
  • eGFR 30-60 mL/min/1.73 m²: No mandatory dose adjustment per FDA labeling, though KDIGO suggests avoiding high-intensity statins in this range 3
  • eGFR >60 mL/min/1.73 m²: No dose adjustment needed 1

Monitoring Requirements:

  • Monitor for proteinuria and hematuria, particularly at higher doses and in patients with severe CKD 4
  • Recent evidence shows rosuvastatin carries a dose-dependent risk of new-onset albuminuria 5
  • 44% of patients with eGFR <30 mL/min/1.73 m² are inappropriately prescribed high-dose rosuvastatin (20-40 mg daily) exceeding FDA recommendations 4

Common Prescribing Errors to Avoid

The most critical pitfall is prescribing rosuvastatin doses >10 mg daily in patients with eGFR <30 mL/min/1.73 m². This occurs frequently in clinical practice and increases the risk of hematuria, proteinuria, and potentially kidney failure with replacement therapy 4.

Cardiovascular Benefit Persists in Advanced CKD

The cardiovascular benefits of statins, including rosuvastatin, continue even in advanced CKD stages. Patients with CKD remain at markedly increased cardiovascular risk, and lipid-lowering therapy should not be withheld based solely on reduced kidney function 2. The KDIGO 2013 lipid guideline recommends statin therapy for adults ≥50 years with eGFR <60 mL/min/1.73 m² who are not on dialysis 6.

Alternative Considerations

If concerns about rosuvastatin-associated kidney effects arise (particularly proteinuria or hematuria), atorvastatin represents a reasonable alternative as it requires no dose adjustment for kidney disease and may have a more favorable renal safety profile 7, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.